Tuesday, Aug 29, 1989
South San Francisco, Calif. -- August 29, 1989 --Genentech, Inc., today announced the appointment of M. David MacFarlane, Ph.D., as vice president of regulatory affairs. MacFarlane, 49, joins Genentech after eleven years with Glaxo Inc., most recently as vice president of regulatory affairs. He succeeds Allen F. Woodhour, Ph.D., who retires on October 1.
MacFarlane began his career with Glaxo in 1978 as director of research and professional services, after holding a similar position at Meyer Inc. since 1974. In 1980, MacFarlane was promoted to director of regulatory affairs. He was named vice president in 1987, responsible for establishing and implementing strategies and policies to enhance the company's interaction with the Food and Drug Administration regarding new drug approvals.
Prior to his industry experience, MacFarlane was assistant professor of clinical pharmacology at the University of Southern California and was an instructor of pharmacology at Kirksville College of Osteophathic Medicine in Kirksville, Missouri.
He earned a Ph.D. in Pharmacology from Georgetown University and a B.S. from the New England College of Pharmacy (now Northeastern University, School of Pharmacy. )
Genentech is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #